Impact of drug discovery on stem cell biology

Biochemical and Biophysical Research Communications

Volumn 383, Issue 3, 2009, Pages 275-279

  Zhang, Xiu Zhen ^a   Li, Xue Juan ^a   Ji, Hong Fang ^a   Zhang, Hong Yu ^b  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

^b Huazhong Agricultural University   (China)

Author keywords

Chemical biology; Drug discovery; Rational design; Stem cells

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 6 BROMOINDIRUBIN; 6 BROMUMOINDIRUBIN 3' OXIME; ANTIDIABETIC AGENT; AZACITIDINE; BETA CATENIN; CHIR 99021; CYCLOPAMINE; DEXAMETHASONE; FASUDIL; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN NODAL; RETINOIC ACID; ROLIPRAM; SB 431452; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; WNT PROTEIN;

ACNE VULGARIS; ADIPOCYTE; ADULT STEM CELL; BLASTOCYST; BONE DEVELOPMENT; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CUTANEOUS T CELL LYMPHOMA; CYTOLOGY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TARGETING; EMBRYONIC STEM CELL; ERYTHROPOIESIS; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; KERATOSIS; MELANOGENESIS; MESENCHYMAL STEM CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REGENERATIVE MEDICINE; SHORT SURVEY; STEM CELL; TISSUE ENGINEERING;

ANIMALS; DRUG DISCOVERY; HUMANS; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 67349219132     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.04.026     Document Type: Short Survey

References (48)

1. Hughes B. 2007 FDA drug approvals: a year of flux. Nat. Rev. Drug Discov. 7 (2008) 107-109
2. Uitdehaag J.C. Where is the optimism? Warrior teachings to regain the drug discovery spirit. Drug Discov. Today 12 (2007) 105-107
3. Schreiber S.L. Small molecules: the missing link in the central dogma. Nat. Chem. Biol. 1 (2005) 64-66
4. Murry C.E., and Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132 (2008) 661-680
5. Sato N., Sanjuan I.M., Heke M., Uchida M., Naef F., and Brivanlou A.H. Molecular signature of human embryonic stem cells and its comparison with the mouse. Dev. Biol. 260 (2003) 404-413
6. Emre N., Coleman R., and Ding S. A chemical approach to stem cell biology. Curr. Opin. Chem. Biol. 11 (2007) 252-258
7. Schugar R.C., Robbins P.D., and Deasy B.M. Small molecules in stem cell self-renewal and differentiation. Gene Ther. 15 (2008) 126-135
8. Tsuji-Takayama K., Inoue T., Ijiri Y., Otani T., Motoda R., Nakamura S., and Orita K. Demethylating agent, 5-azacytidine, reverses differentiation of embryonic stem cells. Biochem. Biophys. Res. Commun. 323 (2004) 86-90
9. Fukuda K. Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering. Artif. Organs 25 (2001) 187-193
10. Yoon B.S., Yoo S.J., Lee J.E., You S., Lee H.T., and Yoon H.S. Enhanced differentiation of human embryonic stem cells into cardiomyocytes by combining hanging drop culture and 5-azacytidine treatment. Differentiation 74 (2006) 149-159
11. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., and Melton D.A. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 26 (2008) 795-797
12. Wernig M., Lengner C.J., Hanna J., Lodato M.A., Steine E., Foreman R., Staerk J., Markoulaki S., and Jaenisch R. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat. Biotechnol. 26 (2008) 916-924
13. Baus E., Andris F., Dubois P.M., Urbain J., and Leo O. Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes. J. Immunol. 156 (1996) 4555-4561
14. Srivastava A.S., Kaushal S., Mishra R., Lane T.A., and Carrier E. Dexamethasone facilitates erythropoiesis in murine embryonic stem cells differentiating into hematopoietic cells in vitro. Biochem. Biophys. Res. Commun. 346 (2006) 508-516
15. Buttery L.D., Bourne S., Xynos J.D., Wood H., Hughes F.J., Hughes S.P., Episkopou V., and Polak J.M. Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells. Tissue Eng. 7 (2001) 89-99
16. Yamane T., Hayashi S., Mizoguchi M., Yamazaki H., and Kunisada T. Derivation of melanocytes from embryonic stem cells in culture. Dev. Dyn. 216 (1999) 450-458
17. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., and Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
18. Schuldiner M., Eiges R., Eden A., Yanuka O., Itskovitz-Eldor J., Goldstein R.S., and Benvenisty N. Induced neuronal differentiation of human embryonic stem cells. Brain Res. 913 (2001) 201-205
19. Guan K., Chang H., Rolletschek A., and Wobus A.M. Embryonic stem cell-derived neurogenesis. Retinoic acid induction and lineage selection of neuronal cells. Cell Tissue Res. 305 (2001) 171-176
20. Wobus A.M., Kaomei G., Shan J., Wellner M.C., Rohwedel J., Ji G., Fleischmann B., Katus H.A., Hescheler J., and Franz W.M. Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 29 (1997) 1525-1539
21. Dani C., Smith A.G., Dessolin S., Leroy P., Staccini L., Villageois P., Darimont C., and Ailhaud G. Differentiation of embryonic stem cells into adipocytes in vitro. J. Cell Sci. 110 Pt. 11 (1997) 1279-1285
22. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16 (2002) 669-694
23. Hsieh J., Nakashima K., Kuwabara T., Mejia E., and Gage F.H. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl. Acad. Sci. USA 101 (2004) 16659-16664
24. Hirooka Y., and Shimokawa H. Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases. Am. J. Cardiovasc. Drugs 5 (2005) 31-39
25. Hu E., and Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin. Ther. Targets 9 (2005) 715-736
26. Watanabe K., Ueno M., Kamiya D., Nishiyama A., Matsumura M., Wataya T., Takahashi J.B., Nishikawa S., Nishikawa S., Muguruma K., and Sasai Y. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25 (2007) 681-686
27. Meijer L., Skaltsounis A.L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X.P., Vonica C.A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S.M., Pearl L., and Greengard P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10 (2003) 1255-1266
28. Sato N., Meijer L., Skaltsounis L., Greengard P., and Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10 (2004) 55-63
29. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
30. Qi X., Li T.G., Hao J., Hu J., Wang J., Simmons H., Miura S., Mishina Y., and Zhao G.Q. BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. USA 101 (2004) 6027-6032
31. Li J., Wang G., Wang C., Zhao Y., Zhang H., Tan Z., Song Z., Ding M., and Deng H. MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal. Differentiation 75 (2007) 299-307
32. Sebolt-Leopold J.S., Herrera R., and Ohren J.F. The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment. Recent Results Cancer Res. 172 (2007) 155-167
33. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., and Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36 (2008) D901-D906
34. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34 (2006) D668-D672
35. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48 Suppl. 1 (2001) S20-S26
36. Burkert J., Wright N.A., and Alison M.R. Stem cells and cancer: an intimate relationship. J. Pathol. 209 (2006) 287-297
37. Clarke M.F., and Fuller M. Stem cells and cancer: two faces of eve. Cell 124 (2006) 1111-1115
38. Kohno M., and Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog. Cell Cycle Res. 5 (2003) 219-224
39. Manetti F., and Botta M. Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). Curr. Pharm. Des. 9 (2003) 567-581
40. Burdon T., Chambers I., Stracey C., Niwa H., and Smith A. Signaling mechanisms regulating self-renewal and differentiation of pluripotent embryonic stem cells. Cells Tissues Organs 165 (1999) 131-143
41. Ying Q.L., Wray J., Nichols J., Batlle-Morera L., Doble B., Woodgett J., Cohen P., and Smith A. The ground state of embryonic stem cell self-renewal. Nature 453 (2008) 519-523
42. Hjelmeland M.D., Hjelmeland A.B., Sathornsumetee S., Reese E.D., Herbstreith M.H., Laping N.J., Friedman H.S., Bigner D.D., Wang X.F., and Rich J.N. SB431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3 (2004) 737-745
43. Vallier L., Reynolds D., and Pedersen R.A. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev. Biol. 275 (2004) 403-421
44. Watanabe K., Kamiya D., Nishiyama A., Katayama T., Nozaki S., Kawasaki H., Watanabe Y., Mizuseki K., and Sasai Y. Directed differentiation of telencephalic precursors from embryonic stem cells. Nat. Neurosci. 8 (2005) 288-296
45. Smith J.R., Vallier L., Lupo G., Alexander M., Harris W.A., and Pedersen R.A. Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Dev. Biol. 313 (2008) 107-117
46. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., and Melton D.A. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 298 (2002) 597-600
47. McNeish J. Embryonic stem cells in drug discovery. Nat. Rev. Drug Discov. 3 (2004) 70-80
48. Rubin L.L. Stem cells and drug discovery: the beginning of a new era?. Cell 132 (2008) 549-552